EFFECTS OF ERYTHROPOIESIS-STIMULATING AGENTS ON OVERALL SURVIVAL OF IPSS LOW/INT-1 RISK TRANSFUSION INDEPENDENT MYELODYSPLASTIC SYNDROMEPATIENTS, A FISM STUDY

被引：0
|
作者：
Messa, E. [1 ]
Gioia, D. [2 ]
Masiera, E. [2 ]
Castiglione, A. [3 ]
Ceccarelli, M. [3 ]
Salvi, F. [4 ]
Danise, P. [5 ]
Sanna, A. [6 ]
Allione, B. [7 ]
Balleari, E. [8 ]
Poloni, A. [9 ]
Cametti, G. [1 ]
Ferrero, D. [7 ]
Tassara, R. [10 ]
Finelli, C. [11 ]
Bonferroni, M. [12 ]
Ciccone, G. [3 ]
Saglio, G. [13 ]
Levis, A. [2 ]
Santini, V. [6 ]
机构：
[1] ASLTO 5, Dept Internal Med, Turin, Italy
[2] Fdn Italiana Sindromi Mielodisplast Onlus, Hematol, Alessandria, Italy
[3] Azienda Osped Univ Citta Salute & Sci Torino, Piedmont Reference Ctr Canc Epidemiol & Prevent, Turin, Italy
[4] SS Antonio & Biagio Hosp, Hematol Dept, Alessandria, Italy
[5] ASL Salerno, Div Oncohematol Nocera Pagani, Salerno, Italy
[6] Azienda Osped Univ Careggi, Div Hematol, Florence, Italy
[7] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy
[8] IRCCS San Martino, Internal Med Dept, Genoa, Italy
[9] Osped Riuniti, Hematol Dept, Ancona, Italy
[10] ASL2 Savonese, Div Med & Hematol, Savona, Italy
[11] St Orsola Malpighi Univ Hosp, Inst Hematol L&A Seragnoli, Bologna, Italy
[12] Santa Croce & Carle Hosp, Div Hematol, Cuneo, Italy
[13] Mauriziano Hosp, Div Hematol, Turin, Italy
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30206-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
93
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 50 条
  • [21] Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
    U Platzbecker
    H K Al-Ali
    N Gattermann
    D Haase
    V Janzen
    J Krauter
    K Götze
    R Schlenk
    F Nolte
    A Letsch
    O G Ottmann
    A Kündgen
    M Lübbert
    U Germing
    M Wermke
    H Reinhard
    C Weiss
    K Lieder
    G Ehninger
    O Leismann
    A Giagounidis
    Leukemia, 2014, 28 : 696 - 698
  • [22] Transfusion Burden and Outcomes in Patients with Low- or Unspecified-Grade Myelodysplastic Syndromes Treated with Erythropoiesis-Stimulating Agents: Analysis of a United States Commercial Claims Database
    Mehra, Maneesha
    Potluri, Ravi
    He, Jianming
    Rizo, Aleksandra
    Mundle, Suneel
    Bussolari, Jacqueline
    BLOOD, 2016, 128 (22)
  • [23] Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis
    Hedenus, Michael
    Oesterborg, Anders
    Tomita, Dianne
    Bohac, Chet
    Coiffier, Bertrand
    LEUKEMIA & LYMPHOMA, 2012, 53 (11) : 2151 - 2158
  • [24] Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes
    Komrokji, Rami S.
    List, Alan F.
    Khoury, H. Jean
    Lancet, Jeffrey E.
    Jabbour, Elias
    Foudray, Maria C.
    Winski, Shannon L.
    Bell, Stacie
    Rush, Selena Armistead
    Maloney, Lara
    Ptaszynski, Ann Marie
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2011, 118 (21) : 58 - 58
  • [25] Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
    Platzbecker, U.
    Al-Ali, H. K.
    Gattermann, N.
    Haase, D.
    Janzen, V.
    Krauter, J.
    Goetze, K.
    Schlenk, R.
    Nolte, F.
    Letsch, A.
    Ottmann, O. G.
    Kuendgen, A.
    Luebbert, M.
    Germing, U.
    Wermke, M.
    Reinhard, H.
    Weiss, C.
    Lieder, K.
    Ehninger, G.
    Leismann, O.
    Giagounidis, A.
    LEUKEMIA, 2014, 28 (03) : 696 - 698
  • [26] Prognostic Factors Of Response and Survival To Azacitidine (AZA) plus /- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM
    Thepot, Sylvain
    Ben Abdelali, Raouf
    Chevret, Sylvie
    Renneville, Aline
    Rauzy, Odile Beyne
    Prebet, Thomas
    Park, Sophie
    Stamatoullas, Aspasia
    Guerci-Bresler, Agnes
    Cheze, Stephane
    Tertian, Gerard
    Choufi, Bachra
    Legros, Laurence
    Bastie, Jean-Noel
    Delaunay, Jacques
    Wattel, Eric
    Dreyfus, Francois
    Vey, Norbert
    Preudhomme, Claude
    Fenaux, Pierre
    Gardin, Claude
    BLOOD, 2013, 122 (21)
  • [27] Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study
    Sekeres, Mikkael A.
    Santini, Valeria
    Diez-Campelo, Maria
    Komrokji, Rami S.
    Fenaux, Pierre
    Savona, Michael R.
    Madanat, Yazan F.
    Valcarcel-Ferreiras, David
    Oliva, Esther Natalie
    Regnault, Antoine
    Creel, Kristin
    Sengupta, Nishan
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Wan, Ying
    Navada, Shyamala
    Zeidan, Amer M.
    Platzbecker, Uwe
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 529 - 534
  • [28] Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM).
    Park, Sophie
    Zini, Gina
    Andrieu, Valerie
    Levis, Alessandro
    Gioia, Daniela
    Duchayne, Eliane
    Poloni, Antonella
    Balleari, Enrico
    Calabrese, Marco
    Sudaka, Isabelle
    Siguret, Virginie
    Guesnu, Martine
    Kosmider, Olivier
    Fontenay, Michaela
    Sanna, Alessandro
    Lemaire, Pierre
    Beyne-Rauzy, Odile
    Ades, Lionel
    Legros, Laurence
    Danise, Paolo
    Musto, Pellegrino
    Fenaux, Pierre
    Dreyfus, Francois
    Santini, Valeria
    BLOOD, 2012, 120 (21)
  • [29] Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Zhong, Jianhua
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    Hoenekopp, Albert
    MacBeth, Kyle J.
    BLOOD, 2016, 128 (22)
  • [30] Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study
    Parmar, Ambica
    Leitch, Heather A.
    Wells, Richard A.
    Nevill, Thomas J.
    Zhu, Nancy Y.
    Yee, Karen W. L.
    Leber, Brian
    Sabloff, Mitchell
    St-Hilaire, Eve
    Kumar, Rajat
    Geddes, Michelle
    Storring, John
    Kew, Andrea
    Shamy, April
    Elemary, Mohamed
    Lenis, Martha
    Mamedov, Alex
    Buckstein, Rena
    BLOOD, 2015, 126 (23)
12345